Ticker brief
ABCL ABCELLERA BIOLOGICS INC
Consumer, Non-cyclical · Biotechnology
last close
$11.82
1 day
+4.0%
14 days
-5.8%
mkt cap
$2.5B
signals 14d
59
authors 14d
39
crowd 14d
-0.5σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 93% mid · 47 pctile own 1y | IV/HV 1.33× |
| Skew — 25Δ RR 30d | +0.006 31 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +1.77 elevated | 5-session Δ -0.72 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-07-06 (z=4.0) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-16 · now +0.13 (−1 bearish … +1 bullish)
Who spoke39
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @JackPrescottX | C | -0.16 | 5 | +0.43 |
| @DrTomsLens | C | -1.55 | 4 | +0.50 |
| @Tautilas | C | -0.32 | 3 | +0.12 |
| @chad_ventures | C | -0.92 | 3 | +0.40 |
| @sunxliao | B | -0.09 | 3 | +0.33 |
| @wliang | C | -2.48 | 3 | +0.52 |
| @StockChaser_ | C | +0.58 | 2 | +0.58 |
| @HeidingOut | C | -1.46 | 2 | +0.35 |
| @Sebagyeong | C | -1.16 | 2 | +0.10 |
| @OzmosiHealth | C | · | 2 | +0.08 |
| @Quantumup1 | C | +0.10 | 2 | +0.53 |
| @PortfolioArmor | C | -0.24 | 1 | +0.00 |
| @nanalyzetweets | B | +5.59 | 1 | +0.15 |
| @GetPursa | C | +0.10 | 1 | +0.00 |
| @RosannaInvests | B | -2.89 | 1 | +0.25 |
| @JSpitTrades | C | -0.94 | 1 | +0.45 |
| @AlphaScout360 | C | -0.12 | 1 | +0.80 |
| @AISavvyCapital | C | +0.13 | 1 | +0.65 |
| @MARU_X | C | +0.06 | 1 | -0.45 |
| @MMatters22596 | C | -0.73 | 1 | +0.50 |
| @cnfinancewatch | B | -1.23 | 1 | +0.45 |
| @dannycheng2022 | C | -2.64 | 1 | -0.40 |
| @TheWaveCount | C | -0.29 | 1 | -0.45 |
| @snmart | A | -1.61 | 1 | +0.65 |
| @BiopharmIQ | B | · | 1 | +0.25 |
Recent signals30of 59 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @JackPrescottX | +0.10 | Aligns ABCL with skepticism that computers can make difficult biotech development automatically work. | +0.2% | tweet ↗ |
| 2026-10-16 | @DustinHuntwn | +0.10 | Biotech stock list without an explicit trade action or detailed thesis. | +0.2% | tweet ↗ |
| 2026-10-16 | @Mariusz_Invest | +0.20 | Discloses covered-call income earned against ABCL shares. | +0.2% | tweet ↗ |
| 2026-10-15 | @beach_trades | +0.35 | Forecasts SOPH will soon lead the AI-biotech group alongside three peers. | -6.8% | tweet ↗ |
| 2026-10-14 | @HolySmokas | -0.25 | Claims market turmoil and an urgent portfolio response but omits the actual action. | -4.4% | tweet ↗ |
| 2026-10-14 | @chad_ventures | +0.70 | Recaps a system entry at $5 and a subsequent gain exceeding 140% | -4.4% | tweet ↗ |
| 2026-10-14 | @carlosfagar | -0.50 | Predicts HIMS will generate major cash flow and outperform named rivals. | -4.4% | tweet ↗ |
| 2026-10-14 | @wliang | +0.55 | Expresses a bullish Q4 biotechnology view and identifies several constructive breakout and trend setups. | -4.4% | tweet ↗ |
| 2026-10-14 | @KeithTradeSmith | +0.30 | Notes strong Phase 2 results and an Oct. 22 update catalyst for ABCL635. | -4.4% | tweet ↗ |
| 2026-10-14 | @DrTomsLens | +0.30 | Builds a long-term thesis linking HIMS, ABCL and NAUT to personalized peptide treatments and AI-enabled biology. | -4.4% | tweet ↗ |
| 2026-10-14 | @gabz_investing | +0.70 | Recaps large gains following earlier signals. | -4.4% | tweet ↗ |
| 2026-10-13 | @wliang | +0.50 | Explicitly bullish on PDSB's breakout and the broader biotech theme for Q4. | -6.3% | tweet ↗ |
| 2026-10-13 | @R1chardMaur1ce | -0.30 | Reports exiting ABCL to lock in a 40% gain as the stock gives back profits. | -6.3% | tweet ↗ |
| 2026-10-12 | @Quantumup1 | +0.60 | Argues ABCL635 may exceed a $3B opportunity due to efficacy, safety, and monthly dosing. | -6.5% | tweet ↗ |
| 2026-10-12 | @Quantumup1 | +0.45 | Summarizes multiple sell-side peak-sales estimates for ABCL635. | -6.5% | tweet ↗ |
| 2026-10-12 | @wliang | +0.50 | Expects biotech and named stocks to outperform through Q4 and says dips may be worth buying. | -6.5% | tweet ↗ |
| 2026-10-12 | @sunxliao | +0.25 | Added PDSB to the focused biotech watchlist near a multi-year breakout. — Explicitly adds PDSB while presenting a focused biotech watchlist and breakout thesis. | -6.5% | tweet ↗ |
| 2026-10-12 | @zohmbastic | +0.40 | UBS initiated AbCellera at Buy with an $18 target and a bullish commercial thesis. | -6.5% | tweet ↗ |
| 2026-10-12 | @CHItrader | +0.40 | Analyst-coverage roundup lists new ratings and targets; extraction is capped at six tickers. | -6.5% | tweet ↗ |
| 2026-10-12 | @JackPrescottX | +0.65 | UBS argues ABCL's '635 could become a preferred therapy and materially exceed competing peak sales. | -6.5% | tweet ↗ |
| 2026-10-12 | @BioStocks | +0.40 | UBS initiates ABCL at Buy with an $18 price target. | -6.5% | tweet ↗ |
| 2026-10-11 | @InvestmentGuru_ | +0.35 | Discloses that some names on the biotech watchlist are long-term holdings. | -5.8% | tweet ↗ |
| 2026-10-10 | @JackPrescottX | +0.55 | Argues successful military and government deployments can identify durable private-enterprise technology winners. | -5.8% | tweet ↗ |
| 2026-10-10 | @sachinvats | -0.55 | Says ABCL underperformed expectations and the author now avoids biotech. | -5.8% | tweet ↗ |
| 2026-10-10 | @sunxliao | +0.50 | Expects strong bullish continuation in biotech after ARKG's monthly retest and cites several prior leaders. | -5.8% | tweet ↗ |
| 2026-10-09 | @harry03994688 | +0.50 | Presents AI-enabled biotech as a structural turnaround and highlights high-short-interest names benefiting from squeezes. | -5.8% | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.00 | AbCellera scheduled Phase 2 vasomotor-symptom results for ABCL-635 on Oct. 22. | -5.8% | tweet ↗ |
| 2026-10-09 | @BiopharmIQ | +0.25 | Biotech news-and-mover list covering regulatory, enrollment, and data events; ticker list capped at six. | -5.8% | tweet ↗ |
| 2026-10-09 | @snmart | +0.65 | Discloses RKLB as a large, high-conviction long-term holding alongside NBIS and ABCL. | -5.8% | tweet ↗ |
| 2026-10-08 | @StockChaser_ | +0.35 | Expects a Wave 4 correction before support and a subsequent Wave 5 advance; advises against chasing now. | -1.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.